Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a new strategic direction with an increasing focus on low-dose GLP-1 combination therapy, muscle mass maintenance, and US market entry. The company has reported on real-world data from nearly 20,000 patients that demonstrate that patients using the Allurion Program lose weight immediately and through a focus on behavior change, keep the weight off while incre